A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril

Frontiers in Pharmacology

Volumn 3 MAY, Issue , 2012, Pages

  Eberlin, Marion ^a   Mück, Tobias ^a   Michel, Martin C ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Analgesia; Congestive heart failure; Diarrhea; Hypertension; Loperamide; Neutral endopeptidase; Racecadotril

Indexed keywords

ACETORPHAN; ACETYLTHIORPHAN; ATRIAL NATRIURETIC FACTOR; CLONIDINE; DRUG METABOLITE; IRINOTECAN; LOPERAMIDE; MEMBRANE METALLOENDOPEPTIDASE; NALOXONE; NIFUROXAZIDE; OCTREOTIDE; PLACEBO; SINORPHAN; THIORPHAN; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE DIARRHEA; ANALGESIA; ANALGESIC ACTIVITY; ANOREXIA; ARTICLE; ASTHENIA; BURNING SENSATION; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; CONGESTIVE HEART FAILURE; CONSTIPATION; DEHYDRATION; DIARRHEA; DIURESIS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; GASTROINTESTINAL MOTILITY; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NATRIURESIS; NAUSEA; NEUROPROTECTION; NONHUMAN; PAIN; PHARMACODYNAMICS; PRURITUS; PULMONARY ARTERY OCCLUSION PRESSURE; SINGLE DRUG DOSE; VOMITING; WITHDRAWAL SYNDROME;

EID: 84866014485     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00093     Document Type: Article

References (130)

1. Adjroud, O. (1995). Peripheral excita-tory effects of two enkephalinase inhibitors, acetorphan and thior-phan, and an enkephalin analogue, [D-Ala2-Met5]-enkephalinamide, on uterine motility in peri-parturient rats in vivo and in vitro. J. Reprod. Fertil. 104, 181-186
2. Alam, N. H., Ashraf, H., Khan, W. A., Karim, M. M., and Fuchs, G. J. (2003). Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double-blind, randomised, controlled clinical trial. Gut 52, 1419-1423
3. Bado, A., Chicau-Chovet, M., Appia, F., Dubrasquet, M., Lecomte, J. M., and Roze, C. (1987). Acetorphan, an enkephalinase inhibitor, decreases gastric secretion in cats. Peptides 8, 89-93
4. Bado, A., Roze, C., Lewin, M. J. M., and Dubrasquet,M. (1989). Endogenous opioid peptides in the control of food intake in cats. Peptides 10, 967-971
5. Baldi, F., Bianco, M. A., Nardone, G., Pilotto, A., and Zamparo, E. (2009). Focus on acute diarrhoeal disease. World J. Gastroenterol. 15, 3341-3348
6. Baliga, R. S., Zhao, L., Madhani, M., Lopez-Torondel, B.,Visintin, C., Sel-wood, D., Wilkins, M. R., MacAllister, R. J., and Hobbs, A. J. (2008). Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 861-869
7. Baumer, P., Akoue, K., Bergmann, J. F., Chaussade, S., Nepveux, P., Alexandre, C. L., Schwartz, J. C., and Lecomte, J. M. (1989). Ace-torphan, a potent enkephalinase inhibitor, does not modify orocecal and colonic transit times in healthy subjects. Gastroenterol. Clin. Biol. 13, 947-948
8. Baumer, P., Danquechin Dorval, E., Bertrand, J., Vetel, J. M., Schwartz, J. C., and Lecomte, J. M. (1992). Effects of acetorphan, an enkephali-nase inhibitor, on experimental and acute diarrhoea. Gut 33, 753-758
9. Beaugerie, L., Baumer, P., Chaussade, S., Berard, H., Pialoux, G., Le Quintrec, Y., Schwartz, J. C., and Lecomte, J. M. (1996). Treatment of refractory diar-rhoea in AIDS with acetorphan and octreotide: a randomized crossover study. Eur. J. Gastroenterol. Hepatol. 8, 485-489
10. Benouali, S., Berard, H., and Roche, M. (1993). Action of enkephalinase (EC 3.4.24.11) inhibition on the pre-and post-prandial electromyo-graphic patterns of colon in rats. Neuropeptides 24, 299-305
11. Bergmann, J. F., Chaussade, S., Cou-turier, D., Baumer, P., Schwartz, J. C., and Lecomte, J. M. (1992). Effects of acetorphan, an antidiar-rhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers. Aliment. Phar-macol. Ther. 6, 305-313
12. Bourgoin, S., Le Bars, D., Artaud, F., Clot, A-M., Bouboutou, R., Fournier-Zaluski, M-C., Roques, B. P., Hamon, M., and Cesselin, F. (1986). Effects of kelatorphan and other peptidase inhibitors on the in vitro and in vivo release of methionine-enkephalin-like mater-ial from the rat spinal cord. J. Phar-macol. Exp. Ther. 238, 360-366
13. Bourin, M., Malinge, M., Colmbel, M. C., and Vasar, E. (1999). Chole-cystokinin receptor agonists block the jumping behaviour precipitated in morphine-dependent mice by naloxone. Eur. Neuropsychopharma-col. 9, 37-43
14. Bousselmame, R., Eustache, M., Michael-Titus, A., and Costentin, J. (1991a). Chronic inhibition of enkephalinase induces changes in the antinociceptive and locomo-tor effects of the enekephalinase inhibitor acetorphan in rats. Neuropharmacology 30, 865-870
15. Bousselmame, R., Michael-Titus, A., and Costentin, J. (1991b). Desensi-tization of μ-opioid receptors does not modify the analgesia induced by an enkephalinase inhibitor. Eur. J. Pharmacol. 203, 295-297
16. Bralet, J., Mossiat, C., Lecomte, J-M., Charpentier, S., Gros, C., and Schwartz, J-C. (1990). Diuretic and natriuretic responses in rats treated with enkephalinase inhibitors. Eur. J. Pharmacol. 179, 57-64
17. Cezard, J. P., Duhamel, J. F., Meyer, M., Pharaon, I., Bellaiche, M., Maurage, C., Ginies, J. L., Vaillant, J. M., Girardet, J. P., Lamireau, T., Poujol, A., Morali, A., Sarles, J., Olives, J. P., Whately-Smith, C., Audrain, S., and Lecomte, J. M. (2001). Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenterol-ogy 120, 799-805
18. Chacon, J. (2010). Analysis of fac-tors influencing the overall effect of racecadotril on childhood diarrhea. Results from a real-world and post-authorization surveillance study in Venezuela. Ther. Clin. Risk Manag. 6, 293-299
19. Chaussade, S., Hamm, R., Lecomte, J. M., Couturier, D., and Guerre, J. (1988). Effects of an enkephalinase inhibitor on esophageal motility in man. Gastroenterol. Clin. Biol. 12, 793-796
20. Chicau-Chovet, M., Dubrasquet, M., Chariot, J., Tsocas, A., Lecomte, J-M., and Roze, C. (1988). Thiorphan and acetorphan inhibit gastric secre-tion by a cetntral, non-opioid mech-anism in the rat. Eur. J. Pharmacol. 154, 247-254
21. Cleland, J. G., and Swedberg, K. (1998). Lack of efficacy of neutral endopeptiadse inhibitor ecadotril in heart failure. The international ecadotril multi-centre dose-ranging study investigators. Lancet 351, 1657-1658
22. Cojocaru, B., Bocquet, N., Timsit, S., Wille, C., Boursiquot, C., Mar-combes, F., Garel, D., Sannier, N., and Cheron, G. (2002). Effect of racecadotril in the management of acute diarrhea in infants and chil-dren. Arch. Pediatr. 9, 774-779
23. Costentin, J., Suaudeau, C., Florin, S., Meunier, J-C., and Costen. (1998). Nociceptin-induced apparent hyperalgesia in mice as a result of the prevention of opioid autoanal-gesic mechanisms triggered by the stress of an intracerebroventricular injection. Fundam. Clin. Pharmacol. 12, 420-425.
24. de la Baume, S., Brion, F., Dam Trung Truong, M., and Schwartz, J. C. (1988). Evaluation of enkephalinase inhibition in the living mouse, using [3H]acetorphan as a probe. J. Phar-macol. Exp. Ther. 247, 653-660
25. Dehaven-Hudkins, D. L., Cortex Bur-gos, L., Cassel, J. A., Daubert, J. D., Dehaven, R. N., Mansson, E., Nagasaka, H., Yu, G., and Yaksh, T. (1999). Loperamide (ADL 2-1294), an opioid antihyperal-gesic agent with peripheral selec-tivity. J. Pharmacol. Exp. Ther. 289, 494-502
26. Dorval, E. D., Regimbeau, C., Gamelin, E., Picon, L., and Berard, H. (1995). Treatment of acute chemi-cally induced diarrhea by inhibition of enkephalinase. Results of a pilot study. Gastroenterol. Clin. Biol. 19, 27-30
27. Dourmap, N., Michael-Titus, A., and Costentin, J. (1990). Acetorphan, an enkephalinase inhibitor, modulates dopaminergic transmission in rat olfactory tubercle, but not in the nucleus accumbens and striatum. Eur. J. Neurosci. 2, 783-787.
28. Duncan, A. M., James, G. M., Anasta-sopoulos, F., Kladis,A., Briscoe, T. A., and Campbell, D. J. (1999). Interac-tion between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocar-dial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. J. Phar-macol. Exp. Ther. 289, 295-303
29. Dussaule, J. C., Grange, J. D., Wolf, J. P., Lecomte, J. M., Gros, C., Schwartz, J. C., Bodin, F., and Ardail-lou, R. (1991). Effect of sinor-phan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cir-rhotic patients with ascites. J. Clin. Endocrinol. Metab. 72, 653-659
30. Dussaule, J-C., Michel, C., Peraldi, M. N., Lecomte, J. M., Gros, C., Mignon, F., and Ardaillou, R. (1993). Inhibi-tion of neutral endopeptidease stim-ulates renal sodium excretion and patients with chronic renal failure. Clin. Sci. 84, 31-39
31. Duval-Ilfah, Y., Barard, H., Baumer, P., Guillaume, P., Raibaud, P., Joulin, Y., and Lecomte, M. J. (1999). Effects of racecadotril and loperamide on bac-terial proliferation and on the cen-tral nervous system of the newborn gnotobiotic piglet. Aliment. Phar-macol. Ther. 13(Suppl. 6), 9-14
32. Dzolic, M. R., Bokszanska, A., Koren-hof, A. M., Kaplan, C. D., Dzolic, M., Rupreht, J., Zijlstra, F. J., Brinkman, E. C., and Cappendijk, S. L. (1992). The effects of orally active enkephalinase inhibitors on mor-phine withdrawal syndrome. Neu-roreport 3, 637-640
33. Farthing, M. J. (2000). Diarrhoea: a sig-nificant worldwide problem. Int. J. Antimicrob. Agents 14, 65-69
34. Farthing, M. J. (2006). Antisecretory drugs for diarrheal disease. Dig. Dis. 24, 47-58
35. Favrat, B., Burnier, M., Nussberger, J., Lecomte, J. M., Brouard, R., Waeber, B., and Brunner, H. R. (1995). Neutral endopeptidase ver-sus angiotensin converting enzyme inhibition in essential hypertension. J. Hypertens. 13, 797-804
36. Fink, C. A., Carlson, J. E., McTaggart, P. A., Qiao, Y., Webb, R., Chate-lain, R., Jeng, A. Y., and Trapani, A. J. (1996). Mercaptoacyl dipepti-dases as orally active dual inhibitors or angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 29, 3158-3168
37. Fink, C. A., Qiao, Y., Berry, C. J., Sakane, Y., Ghai, R. D., and Trapani, A. J. (1995). New α-thiol dipeptide dual inhibitors of angiotensin-I convert-ing enzyme and neutral endopepti-dase EC 3.4.24.11. J. Med. Chem. 38, 5023-5030
38. Fournet-Bourguignon, M. P., Illiano, S., Lenaers, A., and Teisseire, B. (1992). Decrease in enkephalinase A number in kidney membranes from hypercholesterolemic and hyperten-sive rats. J. Recept. Res. 12, 401-412.
39. Gallelli, L., Colosimo, M., tolotta, G. A., Falcone, D., Luberto, L., Curto, L. S., Rende, P., Mazzei, F., Marigliano, N. M., De Sarro, G., and Cucchiara, S. (2010). Prospec-tive randomized double-blind trial of racecadotril compared with lop-eramide in elderly people with gas-troenteritis living in nursing homes. Eur. J. Clin. Pharmacol. 66, 137-144.
40. Giros, B., Gros, C., Schwartz, J. C., Danvy, D., Plaquevent, J. C., Duhamel, P., Vlaiculescu, A., Cos-tentin, J., and Lecomte, J. M. (1987). Enantiomers of thiorphan and acetorphan: correlation between enkephalinase inhibition, protection of endogenous enkephalins and behavioral effects. J. Pharmacol. Exp. Ther. 243, 666-673
41. Giros, B., Llorens-Cortes, C., Gros, C., and Schwartz, J-C. (1986). The endogenous tripeptide Tyr-Gly-Gly as a possible metabolite of opi-oid peptides in rat brain: identifica-tion, regional distribution, effects of lesions and formation in depolarized slices. Peptides 7, 669-677
42. Gray, A. M., Nevinson, M. J., and Sewell, R. D. (1999). The involve-ment of opioidergic and nora-drenergic mechanisms in nefopam antinociception. Eur. J. Pharmacol. 365, 149-157
43. Gray, A. M., Spencer, P. S., and Sewell, R. D. (1998). The involvement of the opiodergic system in the antinoci-ceptive mechanism of action of anti-depressant compounds. Br. J. Phar-macol. 124, 669-674
44. Grimaud, J. C., Bouvier, M., Naudy, B., and Salducci, J. (1989). Non-cholinergic neural excitation of the human rectum induced by acetor-phan, an inhibitor of enkephalinase. Gastroenterol. Clin. Biol.13,799-803
45. Gros, C., Sougue, A., Schwartz, J. C., Duchier, J., Cournot, A., Baumer, P., and Lecomte, J. M. (1989). Pro-tection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan. Proc. Natl. Acad. Sci. U.S.A. 86, 7580-7584
46. Gros, C., Souque, A., and Schwartz, J. C. (1990a). Inactivation of atrial natri-uretic factor in mice in vivo: crucialrole of enkephalinase (EC 3.4.24.11). Eur. J. Pharmacol. 179, 45-56
47. Gros, C., Souque,A., and Schwartz, J-C. (1990b). Degradation of atrial natri-uretic factor in mouse blood in vitro and in vivo: role of enkephalinase (EC 3.4.24.11). Neuropeptides 17, 1-5
48. Guarino, A., Albano, F., Ashkenazi, S., Gendrel, D., Hoekstra, J. H., Shamir, R., and Szajewska, H. (2008). European Society for Paedriatic Gastroenterology, Hepatology, and Nutrition/European Society for Pae-diatric Infections Diseases evidence-based guidelines for the manage-ment of acute gastroenteritis in chil-dren in Europe. J. Pediatr. Gastroen-terol. Nutr. 46(Suppl. 2), S81-S184.
49. Guarino, A., Buccigrossi, V., and Armellino, C. (2009). Colon in acute intestinal infection. J. Pediatr. Gas-troenterol. Nutr. 48(Suppl. 2), S58-S62
50. Guarino, A., Dupont, C., Gorelov, A. V., Gottrand, F., Lee, J. K., Lin, Z., Lo Vecchio, A., Nguyen, T. D., and Salazar-Lindo, E. (2012). The man-agement of acute diarrhea in chil-dren in developed and developing areas: from evidence base to clinical practice. Expert Opin. Pharmacother. 13, 17-26
51. Gutierrez Castrelion, P., Polanco Allue, I., and Salazar-Lindo, E. (2010). An evidence based Iberic-Latin American guideline for acute gas-troenteritis management in infants and prescholars. Ann. Pediatr. 73, 220.e1-220.e20.
52. Haaz, M. C., Riche, C., Rivory, L. P., and Robert, J. (1998a). Biosynthesis of an aminopiperidino metabo-lite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycampthothecine] by human hepatic mircosomes. Drug Metab. Dispos. 26, 769-774.
53. Haaz,M. C.,Rivory,L.,Riche,C.,Vernillet,L.,and Robert,J. (1998b). Metab-olism of irinotecan (CPT-11) by human hepatic microsomes: partic-ipation of cytochrome P-450 3A and drug interactions. Cancer Res. 58, 468-472
54. Hamza, H., Khalifa, H. B., Baumer, P., Berard, H., and Lecomte, J. M. (1999). Racecadotril versus placebo in the treatment of acute diarrhoea in adults. Aliment. Pharmacol. Ther. 13(Suppl. 6), 15-19
55. Hartmann, F., Poirier, M. F., Bour-del, M. C., Loo, H., Lecomte, J. M., and Schwartz, J. C. (1991). Comparison of acetorphan with clonidine for opiate withdrawal symptoms. Am. J. Psychiatry 148, 627-629
56. Hinterleitner, T. A., Petritsch, W., Dimsity, G., Berard, H., Lecomte, J. M., and Krejs, G. J. (1997). Acetorphan prevents cholera-toxin-induced water and electrolyte secre-tion in the human jejunum. Eur. J. Gastroenterol. Hepatol. 9, 887-891.
57. Huighebaert, S., Awouters, F., and Tyt-gat, G. N. (2003). Racecadotril versus loperamide: antidiarrheal research revisited. Dig. Dis. Sci. 48, 239-250.
58. Ito, H., Majima, M., Nakajima, S., Hayashi, I., Katori, M., and Izumi, T. (1999). Effect of prolonged adminis-tration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. Br. J. Pharma-col. 126, 613-620.
59. Jivegard, L., Pollard, H., Moreau, J., Schwartz, J. C., Thune, A., and Svanik, J. (1989). Naloxone-reversible inhibition of gall-bladder mucosal fluid secretion in experi-mental cholecystitis in the cat by ace-torphan, an enkephalinase inhibitor. Clin. Sci. 77, 49-54.
60. Kahn, J. C., Patey, M., Dubois-Rande, J. L., Merlet, P., Castaigne, A., Lim-Alexandre, C., Lecomte, J. M., Duboc, D., Gros, C., and Schwartz, J. C. (1990). Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 335, 118-119.
61. Kayser, V., Fournier-Zaluski, M. C., Guildbaud, G., and Roques, B. P. (1989). Potent antinociceptive effects of kelatorphan (a highly efficient inhibitor of multiple enkephalin-degrading enzymes) systemically administered in normal and arthritic rats. Brain Res. 497, 94-101.
62. Kayser, V., and Guilbaud, G. (1983). The analgesic effects of morphine, but not those of the enkephalinase inhibitor thiorphan, are enhanced in arthritic rats. Brain Res. 267, 131-138.
63. Khallouk-Bousselmame, R., and Cos-tentin, J. (1994). Locomotor and analgesic effects of morphine and acetorphan in rats chronically treated with morphin or thiorphan. Eur. Neuropsychopharmacol. 4, 137-143.
64. Kimura, M., Umemura, K., Ohashi, K., and Nakashima, M. (1998). Effect of ecadotril, a neutral endopeptidase inhibitor, on myocardial hypertro-phy in the rat aortic insufficiency model. Can. J. Cardiol. 14, 63-68.
65. Knisely, J. S., Beardsley, P. M., Aceto, M. D., Balster, R. L., and Har-ris, L. S. (1989). Assessment of the abuse potential of acetorphan, an enkephalinase inhibitor. Drug Alco-hol Depend. 23, 143-151
66. Koletzko, S., and Lentze, M. J. (2008). Leitlinien Pädiatrische Gastroenterologie: akute infek-tiöse Gastroenteritis. Available at: http://www.gpge.de/docs/leitlinien_gastroenteritis.pdf
67. Lambert, D. M., Mergen, F., Berens, C. F., Poupaert, J. H., and Dumont, P. (1995). Synthesis and pharmacological properties of 2-[S-acetylthiorphan]-1,3-diacylaminopropan-2-ol derivatives as chimeric lipid drug carriers con-taining an enkephalinase inhibitor. Pharm. Res. 12, 187-191.
68. Lambert, D. M., Mergen, F., Poupaert, J. H., and Dumont, P. (1993). Anal-gesic potency of S-acetylthiorphan after intravenous administration to mice. Eur. J. Pharmacol. 243, 129-134.
69. Lecomte, J. M. (2000). An overview of clinical studies with racecadotril in adults. Int. J. Antimicrob. Agents 14, 81-87.
70. Lecomte, J-M., Baumer, P., Lim, C., Duchier,J.,Cournot,A.,Dussaule,J-C.,Ardaillou, R., Gros, C., Chaignon, B., Souque, A., and Schwartz, J. C. (1990). Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans. Eur. J. Pharmacol. 179, 65-73.
71. Lecomte, J-M., Costentin, J., Vlaiculescu, A., Chaillet, P., Marcais-Collado, H., Llorens-Cortes, C., Leboyer, M., and Schwarz, J-C. (1986). Pharmacological proper-ties of acetorphan, a parenterally active " enkephalinase" inhibitor. J. Pharmacol. Exp. Ther. 237, 937-944.
72. Lee, J. P., Cheng, K. C., Chung, H. H., Chen, C. T., and Cheng, J. T. (2011). Inhibition of insulin degrad-ing enzyme by racecadotril in the brain of Wistar rats. Horm. Metab. Res. 43, 489-493.
73. Lefrancois, P., Clerc, G., Duchier, J., Lim, C., Lecomte, J. M., Gros, C., and Schwartz, J. C. (1990). Antihyper-tensive activity of sinorphan. Lancet 336, 307-308.
74. Lehert, P., Cheron, G., Calatayud, G. A., Cezard, J-P., Castrellon, P. G., Melendez Garcia, J-M., Santos, M., and Savitha, M. R. (2011). Racecadotril for childhood gas-troenteritis: an individual patient data meta-analysis. Dig. Liver Dis. 43, 707-713.
75. Liberge, M., Riviere, P. M., and Bueno, L. (1988). Influence of enkephali-nase inhibitors on gastric emptying in mice depends on the nature of the meal. Life Sci. 42, 2047-2053.
76. Lishmanov, I. U. B., Maslov, L. N., and Uskina, E. V. (2001). Anti-arrhythmia effects of enkephalinase inhibitors. Eksp. Klin. Farmakol. 64, 28-30.
77. Livingston,S. J.,Sewell,R. D.,Rooney,K. F.,and Smith,H. J. (1988).Ameliora-tion of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan. Psychophar-macology (Berl.) 94, 540-544.
78. Llorens-Cortes, C., Gros, C., and Schwartz, J-C. (1986). Steady-state level and turnover rate of the tripep-tide Tyr-Gly-Gly as indexes of stri-atal enkephalin release in vivo and their reduction during pentobarbi-tal anesthesia. Proc. Natl. Acad. Sci. U.S.A. 83, 6226-6230.
79. Llorens-Cortes, C., Gros, C., Schwartz, J. C., Clot, A. M., and Le Bars, D. (1989). Changes in levels of the tripeptide Tyr-Gly-Gly as an index of enkephalin release in the spinal cord: effects of noxious stim-uli and parenterally-active peptidase inhibitors. Peptides 10, 609-614.
80. Lötvall, J. O., Skoogh, B-E., Barnes, P. J., and Chung, K. F. (1990). Effects of aerosolised substance P on lung resistance in guinea-pigs: a com-parison between inhibition of neu-tral endopeptidase and angiotensin-converting enzyme. Br. J. Pharmacol. 100, 69-72.
81. Lurie,A.,Nadel,J.A.,Roisman,G.,Siney, H., and Dusser, D. J. (1994). Role of neutral endopeptidase and kininase II on substance P-induced increase in nasal obstruction in patients with allergic rhinitis. Am. J. Respir. Crit. Care Med. 149, 113-117.
82. Maertins, T., von Ketz, E., and Goetze,L. (2000).Acute,subchronic, and chronic toxicity of ecadotril in dogs. Am.J.Vet.Res.61, 425-429.
83. Malin, D. H., Lake, J. R., Hamil-ton, R. F., and Skolnick, M. H. (1989). Augmented analgesic effects of enkephalinase inhibitors com-bined with transcranial electrostim-ulation. Life Sci. 44, 1371-1376.
84. Marcais-Collado, H., Uchida, G., Cos-tentin, J., Schwartz, J. C., and Lecomte, J. M. (1987). Naloxone-reversible antidearrheal effects of enkephalinase inhibitors. Eur. J. Pharmacol. 144, 125-132.
85. Matheson, A. J., and Noble, S. (2000). Racecadotril. Drugs 59, 829-835.
86. Medja, F., Lelievre, V., Lebas, F., Leroux, P., Quimet, T., Saria, A., Rougeot, C., Dournaud, P., and Gressens, P. (2006). Thiorphan, a neu-tral endopeptidase inhibitor used for diarrhoea, is neuroprotectivein newborn mice. Brain 129, 3209-3223.
87. Michael-Titus, A., Bousselmame, R., and Costentin, J. (1990a). Stimu-lation of dopamine D2 receptors induces an analgesia involving an opioidergic but non enkephalinergic link. Eur. J. Pharmacol. 187,201-207
88. Michael-Titus, A., Dourmap, N., Cos-tentin,J.,and Schwartz,J. C. (1990b). Role of delta opioid receptors in the effects of inhibitors of enkephalin-degrading peptidases on the hori-zontal and vertical components of locomotion in mice. Neuropeptides 15, 89-100.
89. Michael-Titus, A., and Costentin, J. (1987). Analgesic effects of metapramine and evidence against the involvement of endogenous enkephalins in the analgesia inducec by tricyclic antidepressants. Pain 31, 391-400.
90. Michael-Titus,A., Dourmap, N., Caline, H., Costentin, J., and Schwartz, J. C. (1989). Role of endoge-nous enkephalins in locomotion and nociception studied with peptidase inhibitors in two inbred strains of mice (C57BL/6J and DBA/2J). Neu-ropharmacology 28, 117-122.
91. Michael-Titus, A., Preterre, P., Giros, B., and Costentin, J. (1987). Role of endogenous enkephalins in loco-motion evidenced by acetorphan, an " enkephalinase" inhbitor. J. Pharma-col. Exp. Ther. 243, 1062-1066.
92. Mishima, T., Tanimura, M., Suzuki, G., Todor, A., Sharov, V. G., Tan-hehco, E. J., Goldstein, S., and Sabbah, H. N. (2002). Effects of chronic neutral endopeptidase inhi-bition on the progression of left ventricular dysfunction and remod-eling in dogs with moderate heart failure. Cardiovasc. Drugs Ther. 16, 209-214.
93. Naryzhnaia, N. V., Krylatov, A. V., Maslov, L. N., Lishmanov, I. U. B., Gross, G. J., and Stephano, J. B. (2001). Role of delta opioid recep-tors and their ligands in the devel-opment of adaptive heart protec-tion against arrhythmogenesis. Ross. Fiziol. Zh. Im. I. M. Sechenova 87, 1617-1625.
94. Nichol, G. M., O'Connor, B. J., Lecomte, J. M., Chung, K. F., and Barnes, P. J. (1992). Effect of neutral endopep-tidase inhibitor on airway func-tion and bronchial responsiveness in asthmatic subjects. Eur. J. Clin. Pharmacol. 42, 491-494.
95. Nucera,E.,Schiavino,D.,Altomonte,G., Buonomo, A., Sabato, V., and Patri-arca, G. (2006). Hyperensitivity to racecadotril: a case report. Eur. J. Pediatr. 165, 418-419.
96. O'Connor, C. M., Gattis, W. A., Gheo-rghiade, M., Granger, C. B., Gilbert, J., McKenney, J. M., Messineo, F. C., Burnett, J. C., Katz, S. D., Elkayam, U., Kasper, E. K., Goldstein, S., Cody, R. J., and Massie, B. M. (1999). A randomized trial of ecadotril ver-sus placebo in patients with mild to moderate heart failure: the U.S. Ecadotril pilot safety study. Am. Heart J. 138, 1140-1148.
97. Olivier, N. B., Kutas, S. M., Beals, S., Hanson,B.,and Windram, S. (2000). Short-term effects of ecadotril in dogs with induced congestive heart failure. Am.J.Vet.Res.61, 333-338
98. Piquard, F., Richard, R., Charloux, A., Duotreleau, S., Hannedouche, T., Brandenberger, G., and Geny, B. (2002). Hormonal, renal, hemody-namic responses to acute neutral endopeptidase inhibition in heart transplant patients. J. Appl. Physiol. 93, 569-575.
99. Playford, R. J., and Cox, H. M. (1996). Peptide YY and neuropeptide Y: two peptides intimately involved in elec-trolyte homeostasis. Trends Pharma-col. Sci. 17, 436-438.
100. Prado, D. (2002). A multinational com-parison of racecadotril and lop-eramide in the treatment of acute watery diarrhoea in adults. Scand. J. Gastroenterol. 37, 656-661.
101. Primi, M. P., Bueno, L., Baumer, P., Berard, H., and Lecomte, J. M. (1999). Racecadotril demon-strates intestinal antisecretory activ-ityinvivo.Aliment. Pharmacol. Ther. 13(Suppl. 6), 3-7.
102. Riviere, P. J., and Bueno, L. (1987). Ori-gin of the stimulation of food intake by oral administration of enkephali-nase inhibitors in sheep. Life Sci. 41, 333-339.
103. Roge, J., Baumer, P., Berard, H., Schwartz, J-C., and Lecomte, J-M. (1993). The enkephalinase inhibitor, acetorphan, in acute diarrhoea. A double-blind, controlled clinical trial versus loperamide. Scand. J. Gastroenterol. 28, 352-354.
104. Roques, B. P., Fournie-Zaluski, M-C., Soroca, E., Lecomte, J. M., Mal-froy, B., Llorens, C., and Schwartz, J. C. (1980). The enkephalinase inhibitor thiorphan shows antinoci-ceptive activity in mice. Nature 288, 286-288.
105. Salazar-Lindo, E., Santisteban-Ponce, J., Chea-Woo, E., Gutierrez, M. (2000). Racecadotril in the treatment of acute watery diarrhea in children. N. Engl.J.Med.343, 463-437.
106. Saliba, F., Hagipantelli, R., Misset, J. L., Bastian, G., Vassal, G., Bon-nay, M., Herait, P., Cote, C., Mahjoubi, M., Mignard, D., and Cvitkovic, E. (1998). Pathophysi-ology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J. Clin. Oncol. 16, 2745-2751.
107. Santos, M., Maranon, R., Miguez, C., Vazquez, P., and Sanchez, C. (2009). Use of racecodatril as outpatient treatment for acute gastroenteritis: a prospective, randomized, parallel study. J. Pediatr. 155, 62-67.
108. Schmitt, F., Martinez, F., Ikeni, A., Savoiu, C., Natov, S., Laborde, K., Lacour, B., Grünfeld, J. P., and Hannedouche,T. (1994).Acute renal effects of neutral endopeptidase inhibition in humans. Am. J. Physiol. 267, F20-F27.
109. Schwartz, J. C. (2000). Racecadotril: a new approach to the treatment of diarrhoea. Int. J. Antimicrob. Agents 14, 75-79.
110. Solter, P., Sisson, D., Thomas, W., and Goetze, L. (2000). Intrarenal effects of ecadotril during acute volume expansion in dogs with congestive heart failure. J. Pharmacol. Exp. Ther. 293, 989-995.
111. Spillantini, M. G., Geppetti, P., Fanciul-lacci, M., Michelacci, S., Lecomte, J. M., and Sicuteri, F. (1986). In vivo 'enkephalinase' inhibition by acetor-phan in human plasma and CSF. Eur. J. Pharmacol. 125, 147-150.
112. Stasch, J. P., Hirth-Dietrich, C., Gan-ten, D., and Wegner, M. (1996). Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am.J.Hypertens.9, 795-802.
113. Stasch, J. P., Knorr, A., Wegner, M., and Hirth-Dietrich, C. (1995). Prolonged inhibition of neutral endopeptidase 24.11 by sinorphan in stroke-prone spontaneously hyper-tensive rats. Hypertens. Res. 18, 137-143.
114. Sulpizio, A. C., Pullen, M. A., Edwards, R. M., and Brooks, D. P. (2004). The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat. J. Pharmacol. Exp. Ther. 309, 1141-1147.
115. Szajewska, H., Ruszczynski, M., Chmielewska, A., and Wieczorek, J. (2007). Systematic review: racecadotril in the treatment of acute diarrhoea in children. Aliment. Pharmacol. Ther. 26, 807-813.
116. Takeda, Y., Inaba, S., Furukawa, K., Fujimura, A., Miyamori, I., and Mabuchi, H. (2000). Effects of chronic neutral endopeptidase inhi-bition in rats with cyclosporine-induced hypertension. J. Hypertens. 18, 927-933.
117. Thune, A., Jivegard, L., Pollard, H., Moreau, J., Schwartz, J. C., and Svanik, J. (1992). Location of enkephalinase and functional effects of [Leu5]enkephalin and inhibition of enkephalinase in the feline main pancreatic and bile duct sphincters. Clin. Sci. 82, 169-173.
118. Tormo, R., Polanco, I., Salazar-Lindo, E., and Goulet, O. (2008). Acute infectious diarrhoes in children: new insights in antisecretory treatment with racecadotril. Acta Paediatr. 97, 1008-1015.
119. Turck, D., Berard, H., Fretault, N., and Lecomte, J. M. (1999). Comparison of racecadotril and loperamide in children with acute diarrhoea. Ali-ment. Pharmacol. Ther. 13(Suppl. 6), 27-32.
120. Turvill, J., and Farthing, M. (1997). Enkephalins and enkephalinase inhibitors in intestinal fluid and electrolyte transport. Eur. J. Gastroenterol. Hepatol. 9, 877-880.
121. Uhlen, S., Toursel, F., and Gottrand, F. (2004). Treatment of acute diar-rhea: prescription patterns by pri-vate practice pediatricians. Arch. Pediatr. 11, 903-907.
122. van Kemmel, F. M., Dubuc, I., bourdel, E., Fehrentz, J. A., Martinez, J., and Costentin, J. (1996). A C-terminal cyclic 8-13 neurotensin fragment analog appears less exposed to neprilysin when it crosses the blood-brain barrier than the cerebrospinal fluid-brain barrier in mice. Neurosci. Lett. 217, 58-60.
123. Vetel, J. M., Berard, H., Fretault, N., and Lecomte, J. M. (1999). Compar-ison of racecadotril and loperamide in adults with acute diarrhoea. Ali-ment. Pharmacol. Ther. 13(Suppl. 6), 21-26.
124. Wang, H-H., Shieh, M-J., and Liao, K-F. (2005). A blind, randomized comparison of racecadotril and lop-eramide for stopping acute diarrhea in adults. World J. Gastroenterol. 11, 1540-1543.
125. Wegner, M., Hirth-Dietrich, C., and Stasch, J. P. (1996). Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. CVR 31, 891-898.
126. World Gastroenterology Association. (2008). World Gastroenterology Asso-ciation practice guideline: acute diar-rhea. Available at: http://www.omge.org/assets/downloads/en/pdf/guidelines/01_acute_diarrhea.pdf
127. Wu, H. T., Chang, C. K., Cheng, K. C., Chang, C. H., Yeh, C. H., and Cheng, J. T. (2010). Increase of plasma insulin by racecadotril, aninhibitor of enkephalinase, in Wistar rats. Horm. Metab. Res. 42, 261-267.
128. Xu, Y., Huang, J., Liu, F., Gao, S., and Guo, Q. (2007). Quantitative analysis of racecadotril metabolite in human plasma using a liquid chromatography/tandem mass spec-trometry. J. Chromatogr. B Ana-lyt. Technol. Biomed. Life Sci. 852, 101-107.
129. Ychou, M., Douillard, J. Y., Rougier, P., Adenis, A., Mousseau, M., Dufour, P., Wendling, J. L., Burki, F., Mignard, D., and Marty, M. (2000). Randomized comparison of prophy-lactic antidiarrheal treatment ver-sus non prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. Am. J. Clin. Oncol. 23, 143-148.
130. Zhou, Y., Luo, F., and Han, J. (1990). Enkephalinase inhibitors acetor-phan and SCH34826 potentiate the analgesic effect of low frequency electroacupuncture in rats. Zhen Ci Yan Jiu 15, 310-314.